|
|
Article: Eldecalcitol, an Active Vitamin D3 Derivative, Reduces Incidence of New Vertebral Fractures in Osteoporosis Patients in Phase III Clinical Trial.(Clinical report)
- Article from:
- JCN Newswires
- Article date:
- December 17, 2008
CopyrightCOPYRIGHT 2008 Japan Corporate News Network K.K. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Tokyo, Dec 16, 2008 - (JCN Newswire) - Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. announced today that the active vitamin D3 derivative being co-developed by the two companies for treatment of osteoporosis (generic name: eldecalcitol; Chugai development code: ED-71, Taisho development code: CT-081) significantly reduced the incidence of new vertebral fractures in osteoporosis patients in a randomized, double-blind, comparative trial. Detailed study results will be published in a medical journal and announced at a medical conference.
Eldecalcitol is an active vitamin D3 derivative synthesized by Chugai. It is an agent with superior effect ...